



# INTERNATIONAL CONGRESS 2022

---

BARCELONA Spain, 4 - 6 September

# PROGRAMME

**No Room** **Session** **08:00 - 10:20****Skills workshop: SW1 Exercise, muscle and sleep assessment and interpretation: tips and pitfalls**  
**Tips and pitfalls in exercise, muscle and sleep assessment**

**Aims :** To describe “typical” patterns of responses to exercise, muscle and sleep and to determine methods to distinguish these responses from “anomalous” response profiles that can cause misinterpretation of test results.

**Disease(s) :** **Sleep and breathing disorders**

**Method(s) :** Imaging Physiology Pulmonary function testing Pulmonary rehabilitation Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Respiratory critical care physician, Respiratory physiotherapist, Journalist

**Chairs :** Samuel Verges (Grenoble, France)

**08:00** **Introduction**

**08:00** **Cardiopulmonary exercise testing: breathing patterns and dynamic hyperinflation**  
Pierantonio Laveneziana (Paris, France)

**08:00** **Respiratory and locomotor muscle testing in clinical practice**  
Daniel Langer (Leuven, Belgium)

**08:00** **From different pathophysiological traits revealed by polysomnography to treatment indications or combination of therapies**  
Speaker to be confirmed

**08:00** **Implementation, titration and follow-up of positive airway pressure in patients with obstructive sleep apnoea**  
Athanasia Pataka (Thessaloniki, Greece)

**2** **Session** **09:30 - 11:00****Symposium: Holistic management and rehabilitation of fibrosing interstitial lung diseases**

**Aims :** to describe progress in non-pharmacological management of patients with fibrosing interstitial lung diseases (f-ILDs), including changes in clinical practice and the efficacy of treatments, using a patient-centred approach; to analyse the importance of self-management and the growing role of information and computing technologies in supporting monitoring, rehabilitation and non-pharmacological interventions in f-ILDs, including after lung transplantation; to describe non-pharmacological interventions that aim to relieve symptoms and improve quality of life; to provide an update on dedicated pulmonary rehabilitation strategies and outcome measures in f-ILDs, considering the “new normal” in the context of the pandemic; to discuss new insights into the role of oxygen supplementation in management of breathlessness and the role of ambulatory oxygen in preventing exertional hypoxaemia and maximising the benefits of pulmonary rehabilitation.

**Disease(s) :** **Interstitial lung diseases** **Respiratory critical care**

**Method(s) :** General respiratory patient care Palliative care Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Thoracic surgeon, Respiratory therapist, Journalist

**Chairs :** Anh Tuan Dinh-Xuan (Paris, France), Daiana Stolz (Basel, Switzerland)

**09:30** **Digitally supported self-management and rehabilitation of f-ILD patients**  
Marlies S. Wijzenbeek (Rotterdam, Netherlands)

**09:45** **Supportive care pathways for patients with f-ILDs and the impact of the COVID-19 pandemic**  
Elisabetta Renzoni (London, United Kingdom)

**10:00** **Standards of pulmonary rehabilitation in f-ILDs: where are we?**  
Anne Holland (Fitzroy North (VIC), Australia)

**10:15** **The role of oxygen in the management of dyspnoea in f-ILDs**  
Magnus Ekström (Lyckeby, Sweden)

**10:30** **Discussion and Q&A**

**3** **Session** **09:30 - 11:00****Clinical cases: Lungs on fire: Lung cancer?**

**Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

**Disease(s) :** Respiratory infections Thoracic oncology

**Tag(s) :** Clinical

**Target audience :** Thoracic oncologist, Thoracic surgeon, Adult pulmonologist/Clinician, General practitioner, Clinical researcher, Nurse, Paediatrician, Pathologist, Physician in Pulmonary Training, Respiratory critical care physician, Radiologist, Medical Student

**Chairs :** Georgia Hardavella (Athens, Greece), Torsten Gerriet Blum (Berlin, Germany), Joanna Chorostowska-Wynimko (Warsaw, Poland)

**Discussants :** Andriani Charpidou (Athens, Greece), Sam Janes (London, United Kingdom)

**09:30 Case 1 - Presentation by the session facilitator**  
Andriani Charpidou (Athens, Greece)

**09:52 Case 2 - Presentation by the session facilitator**  
Sam Janes (London, United Kingdom)

**10:14 Case 3 - Presentation by the session facilitator**  
Andriani Charpidou (Athens, Greece)

**10:36 Case 4 - Presentation by the session facilitator**  
Sam Janes (London, United Kingdom)

1

Session

09:30 - 11:00

### State of the art session: Airway diseases

#### Precision medicine for Asthma, COPD and Chronic Cough: New drugs, new biomarkers & new approaches

**Aims :** At the conclusion of the session the participant will be able to:

1. Obtain an understanding of an individual's ageing patterns and understand how these can impact future clinical outcomes
2. Understand the identification and treatment options for people with chronic cough
3. Understand and where applicable be able to apply relevant biomarkers in their clinical practice
4. Gain insight into the barriers and facilitators of using pulmonary rehabilitation as a vehicle to implement a treatable traits approach

**Disease(s) :** Airway diseases Respiratory critical care

**Method(s) :** Epidemiology General respiratory patient care Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

**Chairs :** Apostolos Bossios (Stockholm, Sweden), Emer Kelly (Dublin 4, Ireland)

**09:30 GETomics: integrating the time axis in our understanding of COPD**  
Alvar Agusti Garcia-Navarro (Barcelona, Spain)

**09:45 The interrelatedness of chronic cough and chronic pain**  
Jaclyn Smith (Manchester (Greater Manchester), United Kingdom)

**10:00 Biomarkers for airway diseases in clinical practice**  
Florence Schleich (Liège, Belgium)

**10:15 Airway mucus function, assessment and treatment in asthma and COPD**  
Speaker to be confirmed

**10:30 Discussion and Q&A**

No Room

Session

10:20 - 12:40

### Skills workshop: SW2 Exercise, muscle and sleep assessment and interpretation: tips and pitfalls

#### Tips and pitfalls in exercise, muscle and sleep assessment

**Aims :** To describe "typical" patterns of responses to exercise, muscle and sleep and to determine methods to distinguish these responses from "anomalous" response profiles that can cause misinterpretation of test results.

**Disease(s) :** Sleep and breathing disorders**Method(s) :** Imaging Physiology Pulmonary function testing Pulmonary rehabilitation Respiratory intensive care**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory critical care physician, Journalist**Chairs :** Sophia E. Schiza (Heraklion, Greece)**10:20 Introduction****10:20 Cardiopulmonary exercise testing: breathing patterns and dynamic hyperinflation**  
Michele Schaeffer (Leuven, Belgium)**10:20 Respiratory and locomotor muscle testing in clinical practice**  
Samuel Verges (Grenoble, France)**10:20 From different pathophysiological traits revealed by polysomnography to treatment indications or combination of therapies**  
Speaker to be confirmed**10:20 Implementation, titration and follow-up of positive airway pressure in patients with obstructive sleep apnoea**  
Athanasia Pataka (Thessaloniki, Greece)**4 Session 11:15 - 12:45****Symposium: Lung function testing from preschool age to adolescence: are we done with spirometry?****From technical recommendations to real-life use****Aims :** to update the knowledge of the audience about different lung function tests applicable from preschool age to adolescence by reviewing the most recent technical changes and the clinical use of these techniques; to explore the accuracy of respiratory mechanics measurements in assessment of bronchial reactivity in asthmatic children, the clinical applications of oscillometry in children, the swift ascent of the measurement of ventilation heterogeneity as a primary outcome in cystic fibrosis patients and the accuracy of new developments in spirometry that have been accelerated by the ongoing COVID-19 pandemic.**Disease(s) :** Airway diseases Paediatric respiratory diseases**Method(s) :** Epidemiology Physiology Pulmonary function testing**Tag(s) :** Clinical**Target audience :** Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist**Chairs :** Monika Gappa (Düsseldorf, Germany), Alexander Möller (Zürich, Switzerland)**11:15 The interrupter technique: from reference values to bronchial reactivity assessment**  
Nicole Beydon (Paris, France)**11:30 Oscillometry in children: from reference values to clinical use**  
Enrico Lombardi (Florence, Italy)**11:45 Multiple breath washout techniques: from the technical consensus statement to clinical use**  
Paul Robinson (Sydney (NSW), Australia)**12:00 Spirometry: from implications of new recommendations to home-based spirometry during pandemics**  
Margaret Rosenfeld (Seattle, United States)**12:15 Discussion and Q&A****1 Session 11:15 - 12:45****Clinical trials session: ALERT 1****Aims :** Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.**Tag(s) :** Clinical**Chairs :** Apostolos Bossios (Stockholm, Sweden), Emer Kelly (Dublin 4, Ireland)**11:15**

11:30

11:45

12:00

12:15

12:30

12:45

13:00

**3** Session

11:15 - 12:45

**State of the art session: Thoracic oncology****Unravelling lung cancer mazes; a call for aggressive approach**

**Aims :** This session will highlight the latest developments and controversies in lung cancer management. Four key areas will be covered that have provided critical new observations in the past year and consolidated updates will be offered to improve clinical management of lung cancer patients .

**Disease(s) :** Thoracic oncology

**Method(s) :** Cell and molecular biology Palliative care Surgery

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

**Chairs :** Georgia Hardavella (Athens, Greece), Torsten Gerriet Blum (Berlin, Germany), Joanna Chorostowska-Wynimko (Warsaw, Poland)

**11:15 Does aggressive surgical management of oligometastatic disease pay off?**  
Stefano Elia (Roma (RM), Italy)

**11:30 Recent Advances in NSCLC novel targeted therapies and Implications for Current Practice**  
Jan van Meerbeeck (Edegem (Antwerp), Belgium)

**11:45 Incorporating Immunotherapy in early stage lung cancer management**  
Joanna Chorostowska-Wynimko (Warsaw, Poland)

**12:00 Dyspnoea management in lung cancer; pandora's box?**  
Irene Higginson (London, United Kingdom)

**12:15 Discussion and Q&A**

**2** Session

11:15 - 12:45

**Journal session: The Best of the European Respiratory Journal 2022**

**Aims :** The highlight the best articles published in the European Respiratory Journal over the past 12 months  
To provide an up to date review of the latest developments in 3 key respiratory fields

- interstitial lung disease
- COVID19
- Respiratory Epidemiology

**Disease(s) :** Interstitial lung diseases Respiratory infections

**Method(s) :** Cell and molecular biology Epidemiology General respiratory patient care

**Tag(s) :** Translational

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs :** Anh Tuan Dinh-Xuan (Paris, France), Daiana Stolz (Basel, Switzerland)

**11:15 Interstitial Lung Disease**  
Marlies S. Wijsenbeek (Rotterdam, Netherlands)

**11:30 COVID-19**  
Tobias Welte (Hannover, Germany)

**11:45 Respiratory Epidemiology**  
Isabella Annesi Maesano (Montpellier, France)

**12:00 The ERJ, past, present and future**  
Martin Kolb (Hamilton (ON), Canada)

**12:15 Discussion and Q&A**

## 4 Session

14:15 - 15:45

### Symposium: Cell death modalities regulating the onset and progression of chronic lung diseases The therapeutic potential of modulating cellular fate

**Aims :** to explain the relevance of different cell death modalities upon lung tissue damage in the development of various chronic lung diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease and COVID-19; to differentiate between different cell death modalities and the underlying molecular mechanisms; to describe the immunological and pathological consequences of different cell death modalities; to explain the role of specific cell death modalities in the pathophysiology of chronic lung diseases; to provide insight into the therapeutic potential of cellular fate regulation in chronic lung diseases.

**Disease(s) :** Airway diseases Interstitial lung diseases Respiratory infections

**Method(s) :** Cell and molecular biology

**Tag(s) :** Translational

**Target audience :** Clinical researcher, Medical Student, Paediatrician, Pathologist, Scientist (basic, translational)

**Chairs :** Silke Meiners (Sülfeld, Germany), Reinoud Gosens (Groningen, Netherlands)

**14:15 Introduction to cell death modalities and their role in the progression of chronic lung diseases**  
Simon D. Pouwels (Zuidhorn, Netherlands)

**14:30 Does structural lung cell death contribute to clinical outcomes of patients with COVID-19?**  
Speaker to be confirmed

**14:45 Cell death modalities and their relevance to the development of interstitial lung disease**  
Speaker to be confirmed

**15:00 Clinical importance of cell death modalities in COPD: from necroptosis to ferroptosis**  
Ken Bracke (Ghent, Belgium)

**15:15 Discussion and Q&A**

## 5 Session

14:15 - 15:45

### Symposium: What I learned from Covid-19 to manage my current patients better Onboarding of COVID-19 practices to improve non covid care pathways and outcomes

**Aims :** This session will discuss learnings from COVID-19 that can be implemented in respiratory care or access to care pathways beyond the COVID-pandemic.

**Disease(s) :** Airway diseases Paediatric respiratory diseases Respiratory critical care

**Method(s) :** General respiratory patient care Pulmonary rehabilitation Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs :** Anita Simonds (London, United Kingdom), Thierry Troosters (Leuven, Belgium)

**14:15 Management of severe acute respiratory failure**  
Stefano Nava (Bologna (BO), Italy)

**14:30 How will digital health change care for obstructive lung disease after the pandemic?**  
Niels H. Chavannes (Leiden, Netherlands)

**14:45 Rehabilitation accessible to all**  
Speaker to be confirmed



**15:00 Care for children with chronic respiratory disease**  
Monika Gappa (Düsseldorf, Germany)

**15:15 Discussion and Q&A**

### 3 Session

14:15 - 15:45

#### Clinical cases: Lungs on fire: Pulmonary vascular diseases?

**Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

**Disease(s) :** Pulmonary vascular diseases Respiratory infections

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Physician in Pulmonary Training, Radiologist, Respiratory critical care physician, Medical Student

**Chairs :** Mona Lichtblau (Zürich, Switzerland), Marc Humbert (Le Kremlin-Bicêtre, France), Yochai Adir (Haifa, Israel)

**Discussants :** Silvia Ulrich (Zurich, Switzerland), David Jiménez Castro (Madrid, Spain)

**14:15 Case 1 - Presentation by the session facilitator**  
Silvia Ulrich (Zurich, Switzerland)

**14:37 Case 2 - Presentation by the session facilitator**  
David Jiménez Castro (Madrid, Spain)

**14:59 Case 3 - Presentation by the session facilitator**  
Silvia Ulrich (Zurich, Switzerland)

**15:21 Case 4 - Presentation by the session facilitator**  
David Jiménez Castro (Madrid, Spain)

### 1 Session

14:15 - 15:45

#### State of the art session: Respiratory infections

**Aims :** To review the most relevant topics related to respiratory infection of 2021-2022

**Disease(s) :** Respiratory infections

**Method(s) :** Cell and molecular biology Public health Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist, Journalist

**Chairs :** Eva Polverino (Barcelona, Spain), Holly R. Keir (Dundee (Angus), United Kingdom), Giovanni Sotgiu (Porto Torres (SS), Italy)

**14:15 The lung microbioma and pneumonia: is dysbiosis the new pathway to investigate these infections?**  
Speaker to be confirmed

**14:45 The role of new diagnostics in managing respiratory infections**

**14:30 How the new vaccine technology can modify the history of respiratory infections**  
Tobias Welte (Hannover, Germany)

**15:00 New drugs and regimens in tuberculosis**  
Christoph Lange (Borstel, Germany)

**15:15 Discussion and Q&A**

### No Room Session

14:30 - 16:50

#### Skills workshop: SW3 Exercise, muscle and sleep assessment and interpretation: tips and pitfalls

##### Tips and pitfalls in exercise, muscle and sleep assessment

**Aims :** To describe “typical” patterns of responses to exercise, muscle and sleep and to determine methods to distinguish these responses from “anomalous” response profiles that can cause misinterpretation of test results.

**Disease(s) :** Sleep and breathing disorders**Method(s) :** Imaging Physiology Pulmonary function testing Pulmonary rehabilitation Respiratory intensive care**Tag(s) :** Clinical**Chairs :** Pierantonio Laveneziana (Paris, France)**14:30 Introduction****14:30 Cardiopulmonary exercise testing: breathing patterns and dynamic hyperinflation**  
Pierantonio Laveneziana (Paris, France)**14:30 Respiratory and locomotor muscle testing in clinical practice**  
Daniel Langer (Leuven, Belgium)**14:30 From different pathophysiological traits revealed by polysomnography to treatment indications or combination of therapies**  
Speaker to be confirmed**14:30 Implementation, titration and follow-up of positive airway pressure in patients with obstructive sleep apnoea**  
Athanasia Pataka (Thessaloniki, Greece)**3 Session****16:00 - 17:30****Symposium: Update on pulmonary embolism management****Aims :** to discuss guidelines that help identify risk factors for pulmonary embolism (PE) and venous thromboembolism (VTE); to debate definitions and their major impact on management of the disease (extended vs. short-term anticoagulant therapy); to assess the adequacy of these risk factors and whether treatment with direct-acting oral anticoagulants should reconsider any of them; to review the scores and data available to help decide when to continue or suspend anticoagulant treatment; to review the risk of thrombosis associated with COVID-19; to describe anticoagulation regimens used to treat VTE and prophylaxis to prevent recurrence in hospitalised patients; to explain the proper anticoagulation strategies for hospitalised COVID-19 patients and define the proper anticoagulation for outpatients in the active or convalescent phase of infection.**Disease(s) :** Pulmonary vascular diseases Respiratory infections Thoracic oncology**Method(s) :** General respiratory patient care**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Respiratory critical care physician, Physician in Pulmonary Training, Thoracic oncologist, Thoracic surgeon, Respiratory therapist**Chairs :** Mona Lichtblau (Zürich, Switzerland), Marc Humbert (Le Kremlin-Bicêtre, France), Yochai Adir (Haifa, Israel)**16:00 Cancer-associated thrombosis: case fatality rates and scores to balance the risks and benefits of long-term anticoagulant treatment**  
Marc Carrier (Ottawa (ON), Canada)**16:15 Prevention and treatment of pulmonary embolism related to COVID-19**  
Stéphane Zuily (Nancy, France)**16:30 Relevance of the term “provoked” in the management of PE: PRO**  
Francis Couturaud (Brest, France)**16:45 Relevance of the term “provoked” in the management of PE: CON**  
Speaker to be confirmed**17:00 Discussion and Q&A****5 Session****16:00 - 17:30****Symposium: Post-critical care long COVID: reducing the physical and emotional toll**  
**Pathophysiological mechanisms, assessments and therapeutic options in patients with long COVID following intensive care unit admission****Aims :** to discuss the pathophysiological mechanisms of post-intensive care unit (ICU) long COVID; to explore how to wean from mechanical ventilation and the therapeutic modalities of inpatient physiotherapy and outpatient rehabilitation; to discuss the psychological and cognitive aspects of post-ICU long COVID, particularly the assessment and support of these patients.



**Disease(s) :** Respiratory critical care Respiratory infections**Method(s) :** General respiratory patient care Pulmonary rehabilitation Respiratory intensive care**Tag(s) :** COVID**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist, Journalist**Chairs :** Anita Simonds (London, United Kingdom), Thierry Troosters (Leuven, Belgium)

|              |  |
|--------------|--|
| <b>16:00</b> | <b>Pathophysiology of post-ICU long COVID syndrome</b><br>Speaker to be confirmed  |
| <b>16:15</b> | <b>Prolonged mechanical ventilation and physiotherapy for COVID patients in ICUs</b><br>Nicholas Hart (London, United Kingdom) |
| <b>16:30</b> | <b>Managing anxiety, depression and cognitive impairment to promote recovery</b><br>Speaker to be confirmed                    |
| <b>16:45</b> | <b>Rehabilitation modalities to address physical morbidity and support recovery</b><br>Mara Paneroni (Mazzano (BS), Italy)     |
| <b>17:00</b> | <b>Discussion and Q&amp;A</b>  |

## 1 Session 16:00 - 17:30

### Clinical cases: Lungs on fire: Respiratory infections?

**Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

**Disease(s) :** Respiratory infections**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Physician in Pulmonary Training, Respiratory critical care physician, Radiologist, Nurse, Medical Student**Chairs :** Eva Polverino (Barcelona, Spain), Holly R. Keir (Dundee (Angus), United Kingdom), Giovanni Sotgiu (Porto Torres (SS), Italy)**Discussants :** Daiana Stolz (Basel, Switzerland), James D. Chalmers (Dundee (Angus), United Kingdom)

|              |   |
|--------------|---|
| <b>16:00</b> | <b>Case 1 - Presentation by the session facilitator</b><br>Daiana Stolz (Basel, Switzerland)                  |
| <b>16:22</b> | <b>Case 2 - Presentation by the session facilitator</b><br>James D. Chalmers (Dundee (Angus), United Kingdom) |
| <b>16:44</b> | <b>Case 3 - Presentation by the session facilitator</b><br>Daiana Stolz (Basel, Switzerland)                  |
| <b>17:06</b> | <b>Case 4 - Presentation by the session facilitator</b><br>James D. Chalmers (Dundee (Angus), United Kingdom) |

**No Room** **Session** **08:00 - 10:20****Skills workshop: SW4 Cardiopulmonary rehabilitation beyond the basics**

**Aims :** To describe diagnostic methods and interventions that enhance the comprehensiveness of cardiopulmonary rehabilitation programmes and contribute to a more patient-tailored approach; to describe methods of assessing physical activity level in patients referred for cardiopulmonary rehabilitation and methods of providing cognitive behavioural therapy to promote physical activity; to describe neuromuscular electrical stimulation and the patients referred for cardiopulmonary rehabilitation who could benefit from this treatment; and to describe the incorporation of mindfulness-based interventions into cardiopulmonary rehabilitation and their outcomes.

**Disease(s) :** Airway diseases

**Method(s) :** Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Respiratory therapist, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Journalist

**Chairs :** Heleen Demeyer (Leuven, Belgium)

**08:00 Introduction**

**08:00 Physical activity assessment and intervention**  
Chris Burtin (Diepenbeek, Belgium)

**08:00 Neuromuscular electrical stimulation**  
Speaker to be confirmed

**08:00 Frailty assessment and intervention**  
Roberto Benzo (Rochester, United States)

**08:00 Mindfulness interventions during cardiopulmonary rehabilitation**  
Ingeborg Farver-Vestergaard (Vejle, Denmark)

**3** **Session** **09:30 - 11:00****Symposium: Treatment of acute respiratory failure in chronic obstructive pulmonary disease patients**

**Aims :** to provide an update on and discuss existing and new treatment options for acute respiratory failure due to chronic obstructive pulmonary disease (COPD) exacerbations; to discuss long-term outcomes and treatment options to change the long-term consequences of severe COPD exacerbations.

**Disease(s) :** Airway diseases Respiratory critical care

**Method(s) :** Palliative care Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Technical Assistant, Nurse, Respiratory critical care physician, Respiratory physiotherapist, Journalist

**Chairs :** Leo Heunks (Amsterdam, Netherlands), Miriam Barrecheguren Fernandez (Barcelona, Spain)

**09:30 Evidence-based recommendations for non-invasive ventilation in patients with acute COPD exacerbations**  
Marieke L. Duiverman (Groningen, Netherlands)

**09:45 Nasal high-flow therapy for acute COPD exacerbations: the new kid on the block**  
Paolo Navalesi (Padova, Italy)

**10:00 Invasive mechanical ventilation and extracorporeal CO<sub>2</sub> removal in patients with acute COPD exacerbations**  
Christian Karagiannidis (Cologne, Germany)

**10:15 Long-term outcomes after severe COPD exacerbations**  
Rebecca D'Cruz (London, United Kingdom)

**10:30 Discussion and Q&A**

**5** **Session** **09:30 - 11:00****Symposium: Dangers in the air we breathe**

**Aims :** to present recent scientific highlights about the effects of airborne pollution factors, especially allergens, diesel exhaust particles, microplastics and microtextiles, on the lungs; to compare their effects in children and adults; to discuss the biology of allergen-induced lung disease; to describe biological sex differences in response to exposure to these factors. The dangers of airborne environmental factors to the human lung are of great and diverse interest due to the current strong international focus on climate change and air pollution.

**Disease(s) :** Airway diseases Paediatric respiratory diseases

**Method(s) :** Cell and molecular biology Epidemiology Public health

**Tag(s) :** Translational

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Paediatrician, Scientist (basic, translational)

**Chairs :** Charlotte Suppli Ulrik (Virum, Denmark), Catherine Greene (Dublin 9, Ireland)

**09:30 Overview of environmental factors affecting allergic airway disease**  
Cezmi A. Akdis (Davos, Switzerland)

**09:45 Smoke, smog and aeroallergens: effects on children and adults**  
Mary Rice (Boston, United States)

**10:00 Microplastics and microfibres in the air we breathe**  
Barbro N. Melgert (Groningen, Netherlands)

**10:15 Effects of inhaled diesel exhaust particles on airway inflammation**  
Neeloffer Mookherjee (Winnipeg (MB), Canada)

**10:30 Discussion and Q&A**

## 2 Session

09:30 - 11:00

### Clinical trials session: ALERT 2

**Aims :** Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.

**Tag(s) :** Clinical

**09:30**

**09:45**

**10:00**

**10:15**

**10:30**

**10:45**

**11:00**

**11:15**

## 1 Session

09:30 - 11:00

### State of the art session: Interstitial lung diseases

#### Trends, controversies and open questions in ILD

**Aims :** Interstitial lung diseases comprise many different entities, mainly chronic forms with significant morbidity and mortality, especially in fibrosing subforms. In recent years, significant insights have been gained in many different forms of these rare lung diseases. While being rare ILDs, our knowledge on cystic lung diseases, such as lymphangioleiomyomatosis (LAM), is increasing and new treatment options are on the horizon. Also for different forms of pulmonary complications of autoimmune diseases, which commonly affect the lungs, new treatment options have been licensed recently; however, diagnosing these rare diseases is challenging and an update on these 2 rare lung disease entities will be given. Drug induced lung diseases are an important differential diagnosis of ILDs which are challenging to diagnose and more challenging to treat. The website pneumotox.com guides the clinician through this very complicated disease entity and a structured overview on this disease entity will be given. Finally, one of the most debilitating complications of -mainly fibrosing- ILDs are acute exacerbations - a still neglected field where however new insights have been achieved recently.

**Disease(s) :** Interstitial lung diseases**Method(s) :** Imaging Respiratory intensive care**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Physician in Pulmonary Training, Radiologist**Chairs :** Katerina Antoniou (Heraklion, Greece), Karen Moor (Rotterdam, Netherlands), Sergio Harari (Milano (MI), Italy)**09:30** **New trends in cystic lung diseases**  
Cormac McCarthy (Dublin 4, Ireland)**09:45** **Acute exacerbations of fibrosing ILDs: controversies and new insights**  
Michael Kreuter (Heidelberg, Germany)**10:00** **Pulmonary manifestations in autoimmune diseases**  
Elisabeth Bendstrup (Aarhus N, Denmark)**10:15** **Drug induced lungs: past, present and future**  
Philippe Camus (Dijon, France)**10:30** **Discussion and Q&A****No Room** **Session** **10:40 - 13:00****Skills workshop: SW5 Cardiopulmonary rehabilitation beyond the basics****Aims :** To describe diagnostic methods and interventions that enhance the comprehensiveness of cardiopulmonary rehabilitation programmes and contribute to a more patient-tailored approach; to describe methods of assessing physical activity level in patients referred for cardiopulmonary rehabilitation and methods of providing cognitive behavioural therapy to promote physical activity; to describe neuromuscular electrical stimulation and the patients referred for cardiopulmonary rehabilitation who could benefit from this treatment; and to describe the incorporation of mindfulness-based interventions into cardiopulmonary rehabilitation and their outcomes.**Disease(s) :** Airway diseases**Method(s) :** Pulmonary rehabilitation**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Respiratory therapist, Respiratory physiotherapist, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Journalist**Chairs :** Frits M.E. Franssen (Horn, Netherlands)**10:40** **Introduction****10:40** **Physical activity assessment and intervention**  
Heleen Demeyer (Leuven, Belgium)**10:40** **Neuromuscular electrical stimulation**  
Maurice J.H. Sillen (Horn, Netherlands)**10:40** **Frailty assessment and intervention****10:40** **Mindfulness interventions during cardiopulmonary rehabilitation**  
Speaker to be confirmed**1** **Session** **11:15 - 12:45****Clinical cases: Lungs on fire: Interstitial lung diseases?****Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.**Disease(s) :** Interstitial lung diseases**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Respiratory critical care physician, General practitioner, Physician in Pulmonary Training, Nurse, Radiologist, Pathologist, Thoracic oncologist, Medical Student**Chairs :** Katerina Antoniou (Heraklion, Greece), Sergio Harari (Milano (MI), Italy), Michael Kreuter (Heidelberg, Germany)**Discussants :** Maria Molina Molina (Barcelona, Spain), Paolo Spagnolo (Padova (PD), Italy)

**11:15 Case 1 - Presentation by the session facilitator**  
Maria Molina Molina (Barcelona, Spain)

**11:37 Case 2 - Presentation by the session facilitator**  
Paolo Spagnolo (Padova (PD), Italy)

**11:59 Case 3 - Presentation by the session facilitator**  
Maria Molina Molina (Barcelona, Spain)

**12:21 Case 4 - Presentation by the session facilitator**  
Paolo Spagnolo (Padova (PD), Italy)

### 3 Session

11:15 - 12:45

#### Journal session: Acute respiratory distress syndrome: the path to precision medicine

##### A joint ERS/Lancet session

**Aims :** We propose a session based on a Series of papers commissioned by The Lancet and The Lancet Respiratory Medicine. The session would bring together leaders in the field to provide insights into the pathophysiology and phenotypes of acute respiratory distress syndrome (ARDS), to review current approaches to diagnosis and management in paediatric and adult patients, to consider therapeutic options in development for this heterogeneous syndrome, to discuss the needs of patients with long-term sequelae of ARDS, and to set out future directions for research and clinical practice. This forward-looking session would provide new insights into mechanisms and management for both non-specialists and specialists, with a focus on the goal of precision medicine.

**Disease(s) :** Paediatric respiratory diseases Respiratory critical care

**Method(s) :** Cell and molecular biology Physiology Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Scientist (basic, translational)

**Chairs :** Leo Heunks (Amsterdam, Netherlands), Rebecca Craven (London, United Kingdom), Miriam Barrecheguren Fernandez (Barcelona, Spain)

**11:15 Causes, pathophysiology, and phenotypes of acute respiratory distress syndrome**  
Lorraine Ware (Nashville, United States)

**11:30 Acute respiratory distress syndrome in adults: diagnosis, management, outcomes, and long-term sequelae**  
Danny Mcauley (Belfast (Belfast), United Kingdom)

**11:45 Paediatric acute respiratory distress syndrome: developing management strategies for improved outcomes**  
Martin Kneyber (Groningen, Netherlands)

**12:00 To be confirmed**  
Speaker to be confirmed

**12:15 Discussion and Q&A**

### 4 Session

14:15 - 15:45

#### Symposium: Interstitial lung diseases in connective tissue diseases: patient's journey from diagnosis and new treatment strategies to transplantation

**Aims :** to update attendees about the management of interstitial lung diseases (ILDs) associated with connective tissue diseases (CTD-ILDs), which has recently evolved with the increasing numbers of prescription for antifibrotics in addition to immunosuppressive drugs; to provide an update about diagnostic practice and assess the adjunctive value of a multidisciplinary approach to diagnosis; to describe therapeutic strategies and analyse the timing and contraindications of lung transplant referral as well as post-transplant management and outcomes; to discuss novel insights into the diagnostic procedure and the implication of genetics.

**Disease(s) :** Interstitial lung diseases Pulmonary vascular diseases Respiratory critical care

**Method(s) :** General respiratory patient care Pulmonary function testing Transplantation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Nurse, Respiratory critical care physician, Radiologist, Thoracic surgeon, Respiratory therapist

**Chairs :** Federica Meloni (Pavia (PV), Italy), Tobias Welte (Hannover, Germany)

**14:15 Utility of genetic assessment of patients with CTD-ILDs**  
Antoine Froidure (Bruxelles, Belgium)

- 14:30 CTD-ILDs: diagnosis and new treatment strategies up to transplantation**  
Bruno Crestani (Paris, France)
- 
- 14:45 What are the main challenges when a CTD-ILD patient is referred for lung transplantation?**  
Speaker to be confirmed
- 
- 15:00 New trends in treatment of myositis-associated ILD**  
Speaker to be confirmed
- 
- 15:15 Discussion and Q&A**

## 2 Session 14:15 - 15:45

### Symposium: Evolving questions in chronic obstructive pulmonary disease management Lessons from pathophysiology to epidemiology

**Aims :** to ask challenging questions faced every day when managing patients with chronic obstructive pulmonary disease (COPD); to inform clinicians and researchers about the latest updates concerning diagnosis, management and assessment of COPD covering four areas, namely, the role of eosinophils, the pathophysiology of a disease exacerbation, the relevance of mortality endpoints and the assessment of COPD patients for comorbidities; to interpret and elaborate on recent findings of clinical trials and their relevance to patient practice.

**Disease(s) :** Airway diseases

**Method(s) :** Cell and molecular biology Epidemiology Imaging

**Tag(s) :** Translational

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

**Chairs :** Omar S. Usmani (London, United Kingdom), Ayşe Arzu Yorgancıoğlu (Konak, Turkey), Daiana Stolz (Basel, Switzerland)

- 14:15 Understanding the role of eosinophilic COPD management: are clinical trial data ready for application in everyday clinical care?**  
Mona Bafadhel (Oxford (Oxfordshire), United Kingdom)
- 
- 14:30 What is the best definition of an exacerbation in COPD patients to help demystify clinical trial data?**  
Alberto Papi (Ferrara, Italy)
- 
- 14:45 Mortality and mortality assessment in COPD: is it possible to apply clinical trial data in everyday patient practice?**  
Dave Singh (Manchester, United Kingdom)
- 
- 15:00 Should all patients with COPD undergo body plethysmography, echocardiograms and computed tomography lung scans?**  
MeiLan K. Han (Ann Arbor, United States)
- 
- 15:15 Discussion and Q&A**

## 5 Session 14:15 - 15:45

### Symposium: Utilising exercise testing in pre-operative assessment, rehabilitation and exercise prescription

**Aims :** to provide an overview of the different exercise modalities available to assess exercise capacity, assessment of exercise prescription and rehabilitation; to provide an overview of how exercise testing can be used to assess pre-operative risk and its utility in determining the most appropriate peri-operative care; to describe the importance of activity in healthy adults and patients; to demonstrate how to effectively provide an exercise prescription; to provide attendees with a global understanding of the importance of exercise and how to utilise it in their everyday practice for the benefit of patients.

**Disease(s) :** Airway diseases

**Method(s) :** Physiology Pulmonary rehabilitation Surgery

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Thoracic surgeon, Journalist

**Chairs :** Pierantonio Laveneziana (Paris, France)

- 14:15 Modalities available to assess the exercise response and exercise rehabilitation**  
Sally J. Singh (Leicester (Leicestershire), United Kingdom)



**14:30** **Utilising the cardio-pulmonary exercise test to assess peri-operative risk**  
Speaker to be confirmed

**14:45** **The health-related benefits of increased exercise and activity**

**15:00** **Exercise prescription in health and disease**  
Speaker to be confirmed

**15:15** **Discussion and Q&A**

### 3 Session

14:15 - 15:45

#### Clinical trials session: ALERT 3

**Aims :** Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.

**Tag(s) :** Clinical

**14:15**

**14:30**

**14:45**

**15:00**

**15:15**

**15:30**

**15:45**

**16:00**

### 1 Session

14:15 - 15:45

#### State of the art session: Pulmonary vascular diseases

##### pulmonary hypertension in pulmonary disease

**Aims :** the aim of this state of art symposium is to summarize the vast progress in recent years which has been made in understanding and treating pulmonary hypertension related to underlying lung disease.

The session had the following specific aims

- insight in the biology and epigenetic causes of pulmonary hypertension
- how these insight help to develop novel treatments in the area
- update on the recent trials in pulmonary hypertension
- update on the novel insights of the pulmonary vascular nature of low dlco related pulmonary hypertension

**Disease(s) :** [Interstitial lung diseases](#) [Pulmonary vascular diseases](#) [Respiratory critical care](#)

**Method(s) :** Imaging Physiology Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Patient, Scientist (basic, translational)

**Chairs :** Anton Vonk Noordegraaf (Amsterdam, Netherlands), Silvia Ulrich (Zurich, Switzerland)

**14:15** **The origin and consequence of pulmonary hypertension in lung related disease**  
Joan Albert Barberà Mir (Barcelona, Spain)

**14:30** **Pulmonary hypertension in autoimmune disease**  
Marc Humbert (Le Kremlin-Bicêtre, France)

**14:45** **Failures and succes in treatment of pulmonary hypertension in interstitial lung disease: past present and future**  
Aaron Waxman (Boston, United States)

**15:00** **Low DLCO in pulmonary arterial hypertension: a different vascular phenotype?**  
Esther Jeritza Nossent (Amsterdam, Netherlands)

15:15 Discussion and Q&amp;A

**No Room** **Session** **14:30 - 16:50****Skills workshop: SW6 Cardiopulmonary rehabilitation beyond the basics**

**Aims :** To describe diagnostic methods and interventions that enhance the comprehensiveness of cardiopulmonary rehabilitation programmes and contribute to a more patient-tailored approach; to describe methods of assessing physical activity level in patients referred for cardiopulmonary rehabilitation and methods of providing cognitive behavioural therapy to promote physical activity; to describe neuromuscular electrical stimulation and the patients referred for cardiopulmonary rehabilitation who could benefit from this treatment; and to describe the incorporation of mindfulness-based interventions into cardiopulmonary rehabilitation and their outcomes.

**Disease(s) :** **Airway diseases**

**Method(s) :** Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Respiratory therapist, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Journalist, Physiologist, Respiratory physiotherapist

**14:30 Introduction**

**14:30 Physical activity assessment and intervention**  
Chris Burtin (Diepenbeek, Belgium)

**14:30 Neuromuscular electrical stimulation**  
Speaker to be confirmed

**14:30 Frailty assessment and intervention**  
Roberto Benzo (Rochester, United States)

**14:30 Mindfulness interventions during cardiopulmonary rehabilitation**  
Ingeborg Farver-Vestergaard (Vejle, Denmark)

**6** **Session** **15:45 - 17:00****Symposium: Steps for a successful career in respiratory research****Early career member session 2022**

**Aims :** To present critical steps for a successful career in respiratory research and medicine; to describe how to build and manage a research team and how to publish successful; to discuss challenges and opportunities for younger physicians and scientists in respiratory research; tips for maintaining a healthy work-life-balance;

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Physiologist, Radiologist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

**Chairs :** Daniela Gompelmann (Vienna, Austria), Maxime Patout (Mont-Saint Aignan, France)

**15:45 Building and managing a research team**  
Debby Bogaert (Edinburgh, United Kingdom)

**16:00 Successful publishing in a scientific journal**  
Anh Tuan Dinh-Xuan (Paris, France)

**16:15 Mina Gaga lecture**

**16:30 Time management strategies for clinical-scientist and privacy**  
Niki Ubags (Epalinges, Switzerland)

**16:45 Discussion and Q&A**

**4** **Session** **16:00 - 17:30****Symposium: Lung involvement in common variable immunodeficiency: from diagnosis to lung transplantation**

**Aims :** to describe the physiopathology of common variable immunodeficiency (CVID) and current diagnostic and therapeutic approaches for this disorder and update attendees about recent advances in this context. CVID-associated lung involvement might be due to respiratory infection and bronchiectasis or non-infectious immune-based diffuse interstitial disorders. This clinical picture and the possible contraindications to lung transplant candidacy and challenges in post-transplant follow-up of these patients will be addressed.

**Disease(s) :** Airway diseases Paediatric respiratory diseases Respiratory infections**Method(s) :** General respiratory patient care Pulmonary function testing Transplantation**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Nurse, Paediatrician, Physician in Pulmonary Training, Respiratory physiotherapist, Thoracic surgeon, Respiratory therapist**Chairs :** Federica Meloni (Pavia (PV), Italy), Tobias Welte (Hannover, Germany)

|       |   |
|-------|---|
| 16:00 | <b>Pathogenesis and diagnosis of CVID in paediatric and adult patients</b><br>Isabelle Meyts (Leuven, Belgium)                        |
| 16:15 | <b>Prevention and treatment of pulmonary and extrapulmonary infections in CVID patients</b><br>David M. Lowe (London, United Kingdom) |
| 16:30 | <b>Non-infectious lung involvement in CVID diagnosis and treatment</b><br>Speaker to be confirmed                                     |
| 16:45 | <b>Lung transplant in CVID patients: contraindications and outcomes</b><br>Michael Perch (København Ø, Denmark)                       |
| 17:00 | <b>Discussion and Q&amp;A</b>   |

**2** Session 16:00 - 17:30**Clinical cases: Lungs on fire: Airway diseases?****Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.**Disease(s) :** Airway diseases**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Paediatrician, Physician in Pulmonary Training, Respiratory critical care physician, Nurse, Radiologist, Respiratory physiotherapist, Respiratory therapist, Medical Student**Chairs :** Omar S. Usmani (London, United Kingdom), Ayşe Arzu Yorgancıoğlu (Konak, Turkey), Daiana Stolz (Basel, Switzerland)**Discussants :** Mina Gaga (Athens, Greece), Marc Miravittles (Barcelona (CT), Spain)

|       |   |
|-------|---|
| 16:00 | <b>Case 1 - Presentation by the session facilitator</b><br>Speaker to be confirmed                  |
| 16:22 | <b>Case 2 - Presentation by the session facilitator</b><br>Marc Miravittles (Barcelona (CT), Spain) |
| 16:44 | <b>Case 3 - Presentation by the session facilitator</b><br>Mina Gaga (Athens, Greece)               |
| 17:06 | <b>Case 4 - Presentation by the session facilitator</b><br>Marc Miravittles (Barcelona (CT), Spain) |

**1** Session 16:00 - 17:30**Respiratory medicine meets other disciplines: Update on the diagnosis and treatment of pulmonary hypertension****ERS/ESC guideline on pulmonary hypertension 2022****Aims :** In 2022 the new ESC/ERS guidelines on pulmonary hypertension will be published. This symposium is based on this major achievement of both societies. The aims of this symposium is to - highlight the changes made in comparison to the previous guidelines - To discuss the still unknown areas where the guidelines could not fill the clinical need - to discuss the new definition in a pro and con debate: what will be the clinical consequence and how will this change our diagnosis**Disease(s) :** Pulmonary vascular diseases**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Nurse, Respiratory critical care physician, Patient, Scientist (basic, translational)**Chairs :** Anton Vonk Noordegraaf (Amsterdam, Netherlands), Silvia Ulrich (Zurich, Switzerland)

- 
- 16:00**    **ERS/ESC guideline on pulmonary hypertension: clinical approach, changes from previous guidelines**  
Marius M. Hoeper (Hannover, Germany)
- 
- 16:15**    **Treatment options and recommendations**  
Marion Delcroix (Leuven, Belgium)
- 
- 16:30**    **Comments on the guideline: strength and weakness**  
Sean Gaine (Dublin, Ireland)
- 
- 16:45**    **Interactive cases**  
Mona Lichtblau (Zürich, Switzerland)
- 
- 17:00**    **Discussion and Q&A**
-

**No Room** **Session** **08:00 - 10:20****Skills workshop: SW7 Thoracic ultrasound**

**Aims :** To describe the current use of thoracic ultrasound and to provide participants with the opportunity to perform this technique using training models, simulators, volunteers and patients.

**Disease(s) :** Thoracic oncology Interstitial lung diseases

**Method(s) :** Imaging General respiratory patient care

**Tag(s) :** Clinical

**Target audience :** Radiologist, Thoracic surgeon, Adult pulmonologist/Clinician, Clinical researcher, Respiratory critical care physician, Physician in Pulmonary Training

**Chairs :** Christian B. Laursen (Odense, Denmark)

**08:00** **The normal thoracic cavity**  
Gilles Mangiapan (Creteil, France), Jesper Rømhild Davidsen (Odense C, Denmark)

**08:30** **Pleural effusion and/or pleural thickening**  
Valentina Pinelli (Sarzana, Italy), Morten Bendixen (Skejby, Denmark)

**09:00** **Case studies**  
Rachelle Ascjak (SIGGIEWI, Malta)

**09:30** **Lymph node biopsy using models**  
Rachid Tazi Mezalek (Barcelona, Spain), Konstantina Kontogianni (Heidelberg, Germany)

**3** **Session** **09:30 - 11:00****Clinical cases: Lungs on fire: Paediatric respiratory diseases**

**Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

**Disease(s) :** Paediatric respiratory diseases

**Tag(s) :** Clinical

**Target audience :** Paediatrician, General practitioner, Physician in Pulmonary Training, Clinical researcher, Nurse, Thoracic oncologist, Radiologist, Respiratory physiotherapist, Respiratory therapist

**Chairs :** Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Alexander Möller (Zürich, Switzerland), Cristina Ardura-Garcia (Bern, Switzerland)

**Discussants :** Monika Gappa (Düsseldorf, Germany), Andrew Bush (London, United Kingdom)

**09:30** **Case 1 - Presentation by the session facilitator**  
Monika Gappa (Düsseldorf, Germany)

**09:52** **Case 2 - Presentation by the session facilitator**  
Andrew Bush (London, United Kingdom)

**10:14** **Case 3 - Presentation by the session facilitator**  
Monika Gappa (Düsseldorf, Germany)

**10:36** **Case 4 - Presentation by the session facilitator**  
Andrew Bush (London, United Kingdom)

**4** **Session** **09:30 - 11:00****Primary care session: Asthma diagnosis: new and old approaches to increase primary care capability**

**Aims :** In this primary care session, attendees will understand the latest approaches to the difficult task of diagnosing asthma in clinical practice.

**Disease(s) :** Airway diseases

**Method(s) :** General respiratory patient care Pulmonary function testing

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, General practitioner, Nurse, Physician in Pulmonary Training

**Chairs :** Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom), Chair to be confirmed

- |       |   |
|-------|---|
| 09:30 | <b>The clues for asthma diagnosis in primary care.</b><br>Janwillem W. H. Kocks (Groningen, Netherlands)                              |
| 09:45 | <b>New and old tests for asthma diagnosis in primary care. From peak-flow to FeNO</b><br>Speaker to be confirmed                      |
| 10:00 | <b>Oscillometry, a renewed and suitable tool for asthma diagnosis in primary care?</b><br>Salman Siddiqui (Leicester, United Kingdom) |
| 10:15 | <b>From diagnosis to self-management: supporting the patient journey</b><br>Cláudia Vicente (Coimbra, Portugal)                       |
| 10:30 | <b>Discussion and Q&amp;A</b>   |

## 1 Session 09:30 - 11:00

### State of the art session: Sleep and breathing disorders

**Myth or reality: Is obstructive sleep apnoea really critical for cardiovascular complications? Current evidence in pathophysiology, clinical implications and future perspectives**

**Aims :** This session aims to summarize the current knowledge about the impact of Obstructive Sleep Apnoea on cardiovascular complications. To explain the link between hypoxic burden, associated intracellular mechanisms and cardiovascular comorbidities. To identify critical endpoints of OSA including cardiovascular morbidity, mortality and patient related outcome measures. To summarize current evidence of PAP treatment effects on cardiovascular endpoints. To critically discuss limitations and strengths of current trials and define future research needs.

**Disease(s) :** Sleep and breathing disorders

**Method(s) :** General respiratory patient care Physiology

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Scientist (basic, translational)

**Chairs :** Sophia E. Schiza (Heraklion, Greece), Winfried J. Randerath (Solingen, Germany)

- |       |  |
|-------|--|
| 09:30 | <b>Hypoxic burden and intracellular mechanisms</b><br>Silke Ryan (Dublin, Ireland)   |
| 09:45 | <b>What endpoints really matter? Clinical relevance of morbidity, mortality and patient related outcome measures</b>   |
| 10:00 | <b>Appraisal and critical review of PAP treatment effects on cardiovascular endpoints</b><br>Anita Simonds (London, United Kingdom)                                |
| 10:15 | <b>The future of sleep science: What are the right targets, outcome parameters, innovative studies and methodology?</b><br>Raphael Heinzer (Lausanne, Switzerland) |
| 10:30 | <b>Discussion and Q&amp;A</b>  |

## No Room Session 10:40 - 13:00

### Skills workshop: SW8 Thoracic ultrasound

**Aims :** To describe the current use of thoracic ultrasound and to provide participants with the opportunity to perform this technique using training models, simulators, volunteers and patients.

**Disease(s) :** Thoracic oncology Interstitial lung diseases

**Tag(s) :** Clinical

**Chairs :** Najib M. Rahman (Oxford, United Kingdom)

- |       |  |
|-------|--|
| 10:40 | <b>The normal thoracic cavity</b><br>Rachelle Ascjak (SIGGIEWI, Malta), Rachel Mercer (Winchester, United Kingdom)                     |
| 11:10 | <b>Pleural effusion and/or pleural thickening</b><br>Pia Iben Pietersen (Odense NØ, Denmark), Giovanni Volpicelli (Torino (TO), Italy) |
| 11:40 | <b>Case studies</b>  |



**12:10 Lymph node biopsy using models**  
Rachel Mercer (Winchester, United Kingdom), Morten Bendixen (Skejby, Denmark)

## 1 Session 11:15 - 12:45

### Symposium: The many faces of central sleep apnoea and hypoventilation syndromes

**Aims :** to discuss the phenotypes of central sleep apnoea and the impact of biomarkers on outcomes, new pathophysiological insights and consecutive therapeutic options for obesity hypoventilation, the strengths and limitations of positive airway pressure during the lifetime and the relevance of concomitant pulmonary disease with not only obstructive, but also central, sleep apnoea.

**Disease(s) :** Airway diseases Respiratory critical care Sleep and breathing disorders

**Method(s) :** General respiratory patient care Public health Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Scientist (basic, translational)

**Chairs :** Sophia E. Schiza (Heraklion, Greece), Winfried J. Randerath (Solingen, Germany)

**11:15 Phenotyping and prognostic markers of central sleep apnoea: is treatment of central sleep apnoea necessary?**  
Winfried J. Randerath (Solingen, Germany)

**11:30 Opioid-induced central sleep apnoea: exceptional or epidemic ?**  
Shahrokh Javaheri (Cincinnati, United States)

**11:45 New perspectives in obesity hypoventilation: from pathophysiology to treatment**  
Jean-Louis Pépin (Grenoble, France)

**12:00 Continuous positive airway pressure and non-invasive ventilation in hypoventilation syndromes from childhood to adulthood**  
Marieke L. Duiverman (Groningen, Netherlands)

**12:15 Discussion and Q&A**

## 5 Session 11:15 - 12:45

### Symposium: Management of complicated sarcoidosis

#### Management decisions and dealing with complications

**Aims :** to discuss new insights into the management of complicated sarcoidosis; to discuss the diagnosis and treatment of fibrotic sarcoidosis, one of the most challenging and unmet needs, in depth; to explore the latest insights into the management of complications and co-morbid conditions such as pulmonary hypertension and infections (mainly fungal); to discuss other important extrapulmonary organ involvements such as those of the heart and brain, which frequently confront pulmonologists.

**Disease(s) :** Interstitial lung diseases Pulmonary vascular diseases Respiratory infections

**Method(s) :** General respiratory patient care Respiratory intensive care Transplantation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Patient

**Chairs :** Carlos Robalo Cordeiro (Coimbra, Portugal)

**11:15 Management of fibrotic sarcoidosis**  
Vivienne Kahlmann (Rotterdam, Netherlands)

**11:45 Management of pulmonary hypertension in sarcoidosis**  
Laura Price (London, United Kingdom)

**12:15 Infections as drivers of sarcoidosis**  
Marcel Veltkamp (De Meern, Netherlands)

**12:45 Complex extrapulmonary sarcoidosis: the heart, brain and more**  
Speaker to be confirmed

## 2 Session 11:15 - 12:45

### Clinical cases: Clinical challenges beyond guidelines

**Aims :** To describe controversial aspects of the current guidelines for 1) sepsis management of adults with COVID-19 in the intensive care unit, 2) clinical standards for tuberculosis infection, 3) optimal follow-up after acute pulmonary embolism and 4) imaging of pulmonary embolism in pregnancy; to discuss data underpinning non-adherence and alternative approaches to ongoing recommendations; to propose evidence-based substitute management recommendations for clinicians; to identify areas of concern and to highlight the need for further research.

**Disease(s) :** Respiratory critical care Respiratory infections Pulmonary vascular diseases

**Method(s) :** General respiratory patient care Respiratory intensive care Imaging

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Respiratory critical care physician, General practitioner, Medical Student, Radiologist, Physician in Pulmonary Training, Clinical researcher

**Chairs :** Anita Simonds (London, United Kingdom), Olivier Sitbon (Le Kremlin-Bicêtre, France), Chair to be confirmed

**11:15 Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update**  
Speaker to be confirmed

**11:30 Discussion and Q&A**

**11:37 Clinical Standards for TB Infection**  
Speaker to be confirmed

**11:52 Discussion and Q&A**

**11:59 Optimal follow-up after acute pulmonary embolism**  
Speaker to be confirmed

**12:14 Discussion and Q&A**

**12:21 Guidelines about imaging of pulmonary embolism in pregnancy**  
Speaker to be confirmed

**12:36 Discussion and Q&A**

#### 4 Session 11:15 - 12:45

##### Primary care session: Forgotten issues in COPD: a primary care perspective

**Aims :** Further than pharmacological treatment, other issues and interventions are of main importance to help people to live and cope with COPD and they are usually forgotten. In this session we will increase health-care professionals' knowledge and motivation towards those issues from a primary care perspective. Mental disorders are common in patients with COPD and they need to be assessed and treated accordingly. Rehabilitation programs are very scarce and unreachable for many COPD patients especially in low resource settings where tele-rehabilitation approaches may be unreliable and remote options need to be realistic. The effect of COPD on sexual satisfaction is underappreciated in clinical practice, improved information and communication regarding sexual health is needed. On the same line, early, integrated palliative care for COPD should be developed in primary care

**Disease(s) :** Airway diseases

**Method(s) :** General respiratory patient care Palliative care Pulmonary rehabilitation

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Patient, Respiratory physiotherapist

**Chairs :** Thierry Troosters (Leuven, Belgium), Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom)

**11:15 COPD and mental health**  
Ioanna Tsiligianni (Heraklion (Crete), Greece)

**11:30 Home-PR in a digital world. An alternative for LMIC?**  
Monsur Habib (KHULNA, Bangladesh)

**11:45 COPD and sexual health**  
Speaker to be confirmed

**12:00 Palliative approach to COPD**  
Miriam Johnson (Hull (North Humberside), United Kingdom)

**12:15 Discussion and Q&A**

#### 3 Session 11:15 - 12:45

##### State of the art session: Paediatric respiratory diseases

**Aims :** to provide clinicians with practical take-home messages regarding the key management and health policy issues related to the respiratory health of children and young people; to provide an update on four important topics in paediatric respiratory medicine.

**Disease(s) :** Paediatric respiratory diseases Respiratory infections Sleep and breathing disorders

**Method(s) :** Endoscopy and interventional pulmonology General respiratory patient care Pulmonary function testing

**Tag(s) :** Clinical

**Target audience :** Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training

**Chairs :** Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Alexander Möller (Zürich, Switzerland), Cristina Ardura-Garcia (Bern, Switzerland)

**11:15** **Diagnosis and management of respiratory infections in children and young adults with neurological impairment**  
Marijke Proesmans (Leuven, Belgium)

**11:30** **Paediatric long-term NIV**  
Brigitte Fauroux (Paris, France)

**11:45** **Paediatric interventional bronchoscopy**  
Dirk Schramm (Düsseldorf, Germany)

**12:00** **Respiratory Function Monitoring in NICU and PICU.**  
David Tingay (Melbourne (VIC), Australia)

**12:15** **Discussion and Q&A**

## 2 Session 14:15 - 15:45

### Symposium: Asthma: confusion in diagnosis, recognising comorbidities and understanding pathophysiological connections

**Aims :** to inform clinicians and researchers about the latest updates in significant asthma comorbidities and pathologies that mimic asthma and contribute to difficulties with diagnosis and treatment; to describe in particular conditions that mimic asthma, such as vocal cord dysfunction and dysfunctional breathing, and significant comorbidities, such as chronic rhinosinusitis, vasculitis and eosinophilic granulomatosis with polyangiitis (EGPA); to assess the importance of small airways in asthma.

**Disease(s) :** Airway diseases Interstitial lung diseases

**Method(s) :** Cell and molecular biology Epidemiology Public health

**Tag(s) :** Translational

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

**Chairs :** Katerina Antoniou (Heraklion, Greece), Apostolos Bossios (Stockholm, Sweden)

**14:15** **Vocal cord dysfunction and dysfunctional breathing: the underlying secrets**  
Stephen James Fowler (Preston (Lancashire), United Kingdom)

**14:30** **Difficult-to-manage chronic rhinosinusitis and asthma: two strangers in the same city**  
Vibeke Backer (Copenhagen, Denmark)

**14:45** **Vasculitis, EGPA and eosinophilic asthma: ties of blood**  
Amy Klion (BETHESDA, United States)

**15:00** **Small airways in asthma: looking deep in the lungs**  
Monica Kraft (Tucson, United States)

**15:15** **Discussion and Q&A**

## 1 Session 14:15 - 15:45

### Clinical cases: Imaging clinical cases Challenges in imaging of emphysema and ILD

**Aims :** The use of endobronchial valves as a treatment for emphysema and lung volume reduction surgery (LVRS) are successful procedures for emphysema treatment. CT quantitative analysis software was used to measure lobar volumes and emphysema destruction by lobe.

Chest high resolution CT (HRCT) is the gold standard imaging modality in underlying interstitial lung diseases (ILDs) to recognize specific patterns. In the era of antifibrotic therapies, the central role of imaging to achieve early diagnosis and prognosis is essential. Photon counting CT, a brand new imaging technique has a 0.4 mm resolution which is promising in ILD imaging due to its higher diagnostic accuracy to detect even subclinical fibrotic alterations that occur in ILDs at an early stage.

The aim of the session is to give a case based session with special focus on imaging to understand:

- the role of imaging of emphysema in a preoperative setting, in case of evaluation before endobronchial valve implantation or volume reduction surgery (LVRS) with special focus of available imaging softwares
- the role of new imaging technique, the photon counting CT in comparison with HRCT in ILD imaging
- to recognise the most common ILD patterns on HRCT.

A clinician and a radiologist will evaluate the cases together with the interactive involvement of the audience.

**Disease(s) :** Airway diseases Interstitial lung diseases Sleep and breathing disorders

**Method(s) :** Endoscopy and interventional pulmonology General respiratory patient care Imaging

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic surgeon, Respiratory therapist

**Chairs :** Walter De Wever (Leuven, Belgium), Elbieta Magdalena Grabczak (Warszawa, Poland), Daniela Gompelmann (Vienna, Austria)

**14:15 Patient with lung emphysema: endobronchial valves or surgery?**  
Stephanie Everaerts (Leuven, Belgium)

**14:30 Discussion and Q&A**

**14:37 Patient with lung emphysema: radiological preoperative setting**  
Walter De Wever (Leuven, Belgium)

**14:52 Discussion and Q&A**

**14:59 Patient with ILD: prognostic markers of disease progression?**  
Veronika Müller (Budapest, Hungary)

**15:14 Discussion and Q&A**

**15:21 Patient with ILD: radiological signs and AI possibilities**  
Helmut Prosch (Wien, Austria)

**15:36 Discussion and Q&A**

3

Session

14:15 - 15:45

### State of the art session: Respiratory critical care

- Aims :**
1. To understand the key characteristics of the different ARDS phenotypes and how this affects clinical management.
  2. To understand the pathophysiology of lung injury induced by high respiratory effort, and how clinical management can reduce the risk of lung injury due to high patient effort.
  3. To understand the principles of novel techniques for respiratory monitoring and how clinical application can improve outcome.
  4. To understand the role of different techniques for noninvasive respiratory support in patients with acute hyperemic failure.

**Disease(s) :** Respiratory critical care

**Method(s) :** General respiratory patient care Physiology Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

**Chairs :** Maxime Patout (Mont-Saint Aignan, France), Maria Bonsignore (Palermo, Italy), João Carlos Winck (Vila Nova de Gaia, Portugal)

**14:15 Phenotyping in acute respiratory distress syndrome: clinical implications**  
Carolyn Calfee (San Francisco, United States)

**14:30 Patient self inflicted lung injury: clinical implications**  
Speaker to be confirmed

**14:45 Advanced respiratory monitoring in acute respiratory failure: clinical implications**  
Lise Piquilloud (Lausanne, Switzerland)

**15:00 High Flow Nasal Oxygen or Noninvasive ventilation for patients with acute hypoxemic failure**  
Stefano Nava (Bologna (BO), Italy)

**15:15 Discussion and Q&A**

## No Room Session 14:30 - 16:50

### Skills workshop: SW9 Thoracic ultrasound

**Aims :** To describe the current use of thoracic ultrasound and to provide participants with the opportunity to perform this technique using training models, simulators, volunteers and patients.

**Disease(s) :** Thoracic oncology Interstitial lung diseases

**Tag(s) :** Clinical

**Chairs :** Konstantina Kontogianni (Heidelberg, Germany)

**14:30 The normal thoracic cavity**  
Valentina Pinelli (Sarzana, Italy), Rachel Mercer (Winchester, United Kingdom)

**15:00 Pleural effusion and/or pleural thickening**  
Gilles Mangiapan (Creteil, France), Giovanni Volpicelli (Torino (TO), Italy)

**15:30 Case studies**  
John Wrightson (Oxford, United Kingdom)

**16:00 Lymph node biopsy using models**  
Rachid Tazi Mezalek (Barcelona, Spain), Rachel Mercer (Winchester, United Kingdom)

## 4 Session 16:00 - 17:30

### Symposium: Malignant pleural effusion management: applying the evidence in 2022 Session

**Aims :** to review the current biological understanding and potential mechanisms of malignant effusion progression and the implications for practice; to explain the relationship between anatomy, physiology and symptoms in pleural disease and the implications for practice; to describe evidence about optimal talc pleurodesis, including its use thoracoscopically; to provide insight into the current evidence for adjunctive treatments with indwelling plural catheters and novel indwelling plural catheter devices and their evidence.

**Disease(s) :** Thoracic oncology

**Method(s) :** Cell and molecular biology Endoscopy and interventional pulmonology General respiratory patient care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Pathologist, Radiologist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

**Chairs :** Najib M. Rahman (Oxford, United Kingdom)

**16:00 From malignant effusion to malignant progression: what do translational studies tell us?**  
Rachelle Ascik (SIGGIEWI, Malta)

**16:15 Understanding the impact, treatment response and outcome of malignant pleural effusions**  
Gary Yc Lee (Perth (WA), Australia)

**16:30 Inpatient pleurodesis: translating the evidence into practice**  
Speaker to be confirmed

**16:45 Adjunctive indwelling pleural catheter management: from outpatient talc to drug-eluting catheters**  
Nick Maskell (Bristol (Avon), United Kingdom)

**17:00 Discussion and Q&A**

## 3 Session 16:00 - 17:30

### Clinical cases: Lungs on fire: Respiratory critical care / Sleep and Breathing disorders

**Aims :** To facilitate the presentation of real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

**Disease(s) :** Respiratory critical care Sleep and breathing disorders**Tag(s) :** Clinical**Target audience :** Adult pulmonologist/Clinician, Respiratory critical care physician, General practitioner, Clinical researcher, Paediatrician, Physician in Pulmonary Training, Nurse, Physiologist, Medical Student**Chairs :** Maxime Patout (Mont-Saint Aignan, France), Maria Bonsignore (Palermo, Italy), João Carlos Winck (Vila Nova de Gaia, Portugal)**Discussants :** Marieke L. Duiverman (Groningen, Netherlands), Leo Heunks (Amsterdam, Netherlands)**16:00 Case 1 - Presentation by the session facilitator**  
Marieke L. Duiverman (Groningen, Netherlands)**16:22 Case 2 - Presentation by the session facilitator**  
Leo Heunks (Amsterdam, Netherlands)**16:44 Case 3 - Presentation by the session facilitator**  
Marieke L. Duiverman (Groningen, Netherlands)**17:06 Case 4 - Presentation by the session facilitator**  
Leo Heunks (Amsterdam, Netherlands)**1 Session 16:00 - 17:30****Clinical trials session: ALERT 4****Aims :** Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.**Tag(s) :** Clinical**Chairs :** Walter De Wever (Leuven, Belgium), El bieta Magdalena Grabczak (Warszawa, Poland), Daniela Gompelmann (Vienna, Austria)**16:00****16:15****16:30****16:45****17:00****17:15****17:30****17:45**



| No Room | Session | 09:30 - 13:00 |
|---------|---------|---------------|
|---------|---------|---------------|

Postgraduate course: PG1 Part 1: Cardiovascular and neurological consequences of OSA: an update.

**Aims :** Obstructive sleep apnoea (OSA) is an important health problem, a multifactorial disease resulting in various consequences, exhibiting differences in treatment response and outcomes. This course will attempt to summarise the current knowledge regarding the: Many clinical OSA faces with variable degree of daytime sleepiness, gender differences in terms of OSA symptoms, or differences in the presence of comorbid insomnia resulted in various forms of comorbidities. The heterogeneity of OSA and its cognitive-outcomes especially affecting attention and executive functions,, and a potential bidirectional relationship with dementia focusing on early identification, prevention and treatment strategies. The immediate pathophysiologic mechanisms influences of OSA-enhancing arrhythmogenesis and preventative strategies to mitigate OSA-induced arrhythmogenicity and related adverse outcomes. The physiological and biochemical mechanisms connecting OSA with metabolic syndrome and diabetes, to clinically-meaningful phenotyping, improved prognosis, and personalized treatment. The impact of OSA severity from mild to severe, on risk and outcome of cardiovascular diseases, also discussing existing evidence of what is the impact of OSA with or without CPAP treatment on morbidity and mortality outcomes, highlighting also the challenges that sleep medicine faces regarding the important role of CPAP in patients outcomes and the role of compliance.

**Disease(s) :** Paediatric respiratory diseases Respiratory critical care Sleep and breathing disorders

**Method(s) :** Epidemiology General respiratory patient care Physiology

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs :** Maria Bonsignore (Palermo, Italy), Matteo Bradicich (Zollikoberg, Switzerland)

|       |  |
|-------|--|
| 09:30 | <b>Clinical OSA phenotypes from sleepiness, to mild, to asymptomatic OSA and their relevance</b><br>Sophia E. Schiza (Heraklion, Greece)         |
| 09:50 | <b>Discussion and Q&amp;A</b><br>Sophia E. Schiza (Heraklion, Greece)  |
| 10:00 | <b>Stroke, minimal cognitive impairment/dementia and OSA: a bidirectional relationship?</b><br>Speaker to be confirmed                           |
| 10:20 | <b>Discussion and Q&amp;A</b><br>Speaker to be confirmed   |
| 10:30 | <b>Break</b>   |
| 10:45 | <b>Various pathophysiological mechanisms leading to OSA cardiovascular sequale and their relevance</b><br>Carolina Lombardi (Milano (MI), Italy) |
| 11:05 | <b>Discussion and Q&amp;A</b><br>Carolina Lombardi (Milano (MI), Italy)  |
| 11:15 | <b>What is the impact of OSA with or without CPAP treatment on cardiovascular morbidity and mortality outcomes?</b>                              |
| 11:35 | <b>Discussion and Q&amp;A</b>  |
| 11:45 | <b>Break</b>   |
| 12:00 | <b>Group assignment</b><br>Sophia E. Schiza (Heraklion, Greece), Carolina Lombardi (Milano (MI), Italy), Speaker to be confirmed                 |

| No Room | Session | 14:00 - 17:30 |
|---------|---------|---------------|
|---------|---------|---------------|

Postgraduate course: PG1 Part II: Outcomes in Central Sleep apnea (CSA) and hypoventilation syndromes

**Aims :** The hypoventilation syndromes represent a variety of disorders that affect central ventilatory control, respiratory mechanics, or both. Obesity hypoventilation syndrome is a clinically important disorder with serious cardiovascular and metabolic consequences, increased morbidity and mortality, if unrecognized. CSA represents also a variety of disorders and/or results from various diseases, have a negative impact on patient prognosis depending also in the severity of underlying disease. HF patients with CSA are highly heterogeneous group with clinical relevant subgroups which has different prognosis and treatment response. This course aim to summarize the current knowledge regarding the: 1. early recognition and effective hypoventilation treatment using various currently available treatment modalities with the scope to improve patient-centered outcomes. 2. different clinical phenotypes of CSA in Heart failure (HF) patients , their correlation with prognosis and their relevance for identifying individualized therapeutic strategies targeted to improve morbidity and mortality and in general to improve patient-centered outcomes, 3. Early recognition and effective pre and post operative management of a patient with SDB, use of anaesthetics, towards patient safety and surgery outcomes, 4. Various types of sleep diagnostic test from type I to type IV and their use depending on patient profile, as well as their strengths and limitations.

**Disease(s) :** Paediatric respiratory diseases Respiratory critical care Sleep and breathing disorders

**Method(s) :** Epidemiology General respiratory patient care Physiology

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs :** Dries Testelmans (Leuven, Belgium), Marta Susana Monteiro Drummond Freitas (Maia, Portugal)

**14:00 Clinical phenotypes in CSA: relevance for treatment decision and patients outcomes**  
Winfried J. Randerath (Solingen, Germany)

**14:20 Discussion and Q&A**  
Winfried J. Randerath (Solingen, Germany)

**14:30 Obesity Hypoventilation Syndrome, one size dosen't fit all: which patient will benefit from various therapeutic options**  
Jean-Louis Pépin (Grenoble, France)

**14:50 Discussion and Q&A**  
Jean-Louis Pépin (Grenoble, France)

**15:00 Break**

**15:15 Pre and postoperative evaluation of patients with various forms of SDB: relevance of patient outcomes**  
Özen K. Başoğlu (Izmir, Turkey)

**15:35 Discussion and Q&A**  
Özen K. Başoğlu (Izmir, Turkey)

**15:45 Type I to type IV diagnostic modalities: which one to choose according to various forms of SDB**  
Renata L. Riha (Edinburgh (Edinburgh), United Kingdom)

**16:05 Discussion and Q&A**  
Renata L. Riha (Edinburgh (Edinburgh), United Kingdom)

**16:15 Break**

**16:30 Group assignment**  
Winfried J. Randerath (Solingen, Germany), Jean-Louis Pépin (Grenoble, France), Özen K. Başoğlu (Izmir, Turkey), Renata L. Riha (Edinburgh (Edinburgh), United Kingdom)

No Room

Session

14:00 - 17:30

**Postgraduate course: PG2 Paediatric respiratory diseases: focus on infections**

**Aims :** To provide clinicians with practical take-home messages regarding the key management and health policy issues related to respiratory disease in children focusing on airway and lung infections; to provide a state-of-the art update on four important paediatric topics: SARS-CoV-2, infections in cystic fibrosis, Tuberculosis, complicated pneumonia

**Disease(s) :** Airway diseases Paediatric respiratory diseases Respiratory infections

**Method(s) :** Epidemiology General respiratory patient care Public health

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, General practitioner, Medical Student, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Respiratory therapist

**Chairs :** Stefan Unger (Edinburgh (Edinburgh), United Kingdom), Marijke Proesmans (Leuven, Belgium)

---

|              |   |
|--------------|---|
| <b>14:00</b> | <b>SARS-CoV-2 associated lung infections in children</b><br>Ahmad Kantar (Bergamo (BG), Italy)                                |
| <b>14:20</b> | <b>Discussion and Q&amp;A</b><br>Ahmad Kantar (Bergamo (BG), Italy)   |
| <b>14:30</b> | <b>Infections in children with Cystic Fibrosis</b><br>Speaker to be confirmed   |
| <b>14:50</b> | <b>Discussion and Q&amp;A</b><br>Speaker to be confirmed  |
| <b>15:00</b> | <b>Break</b>  |
| <b>15:15</b> | <b>Update on Lung-Tuberculosis in children</b><br>James Seddon (London, United Kingdom)                                       |
| <b>15:35</b> | <b>Discussion and Q&amp;A</b><br>James Seddon (London, United Kingdom)  |
| <b>15:45</b> | <b>Management of complicated pneumonia in children</b>  |
| <b>16:05</b> | <b>Discussion and Q&amp;A</b>   |
| <b>16:15</b> | <b>Break</b>  |
| <b>16:30</b> | <b>Group assignment</b><br>Ahmad Kantar (Bergamo (BG), Italy), James Seddon (London, United Kingdom), Speaker to be confirmed |

---

|                |                |                      |
|----------------|----------------|----------------------|
| <b>No Room</b> | <b>Session</b> | <b>09:30 - 15:00</b> |
|----------------|----------------|----------------------|

**Postgraduate course: PG3 Pleural disease: Applying the evidence**

**Aims :** The overall aim is to synthesize the large volume of high quality trial data being published in pleural disease. This includes phase III trials in several sub-specialty areas and updated international guidelines, due to be published in early 2022. Specific learning outcomes for each session will include:

- (1) malignant pleural effusion: participants will be able to select the optimal diagnostic strategy, include use of thoracoscopy and direct-to-biopsy approaches, and be able to explain the proven pros and cons of different management options, facilitating patient-centred, evidence-based care
- (2) pleural infection: participants will be able to correctly diagnose and identify patients requiring drainage, adjunctive intrapleural therapies and referral for surgery; they will be able to deploy risk prediction scores and understand relevant translational and anti-microbial data
- (3) pneumothorax: participants will be able to differentiate between patients requiring admission and those suitable for ambulatory management based on recent phase III trials; they will appreciate the importance of familial pneumothorax and ongoing trials including those involving use of suction.
- (4) mesothelioma: participants will be able to select optimal diagnostic and treatment strategies including 1st and 2nd line immunotherapy, the role of regional MDTs and options for early stage disease, including radical surgery and ongoing clinical trials

**Disease(s) :** Respiratory infections Thoracic oncology

**Method(s) :** Endoscopy and interventional pulmonology General respiratory patient care Surgery

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Nurse, Physician in Pulmonary Training, Thoracic oncologist, Thoracic surgeon

**Chairs :** Kevin Blyth (Glasgow (Glasgow), United Kingdom), Nick Maskell (Bristol (Avon), United Kingdom)

|              |   |
|--------------|---|
| <b>09:30</b> | <b>Evidence-based Diagnosis and Management of Malignant Pleural Effusion</b><br>Selina Tsim (Glasgow (Glasgow), United Kingdom)                               |
| <b>09:50</b> | <b>Discussion and Q&amp;A</b><br>Selina Tsim (Glasgow (Glasgow), United Kingdom)  |
| <b>10:00</b> | <b>Interactive case: Malignant pleural effusion</b><br>Radhika Banka (Mumbai (Maharashtra), India)  |
| <b>10:30</b> | <b>Break</b>  |
| <b>10:45</b> | <b>Stratified therapy for Pleural Infection: Integrating outcome prediction, intrapleural therapy and surgery</b><br>Najib M. Rahman (Oxford, United Kingdom) |
| <b>11:05</b> | <b>Discussion and Q&amp;A</b><br>Najib M. Rahman (Oxford, United Kingdom)   |
| <b>11:15</b> | <b>Interactive case: Pleural infection</b><br>Speaker to be confirmed   |
| <b>11:45</b> | <b>Break</b>  |
| <b>12:00</b> | <b>Pneumothorax: Is ambulatory care ready for prime time?</b><br>Rob Hallifax (Oxford (Oxfordshire), United Kingdom)  |
| <b>12:20</b> | <b>Discussion and Q&amp;A</b><br>Rob Hallifax (Oxford (Oxfordshire), United Kingdom)  |
| <b>12:30</b> | <b>Interactive case: Pneumothorax</b><br>Julius P. Janssen (Nijmegen, Netherlands)  |
| <b>13:00</b> | <b>Lunch break</b>  |
| <b>14:00</b> | <b>Mesothelioma: Integrating new therapies, better diagnostics and clinical trials</b><br>Speaker to be confirmed   |
| <b>14:20</b> | <b>Discussion and Q&amp;A</b><br>Speaker to be confirmed  |
| <b>14:30</b> | <b>Interactive case: Mesothelioma</b><br>Anna Bibby (Bristol (Avon), United Kingdom)  |

|         |         |               |
|---------|---------|---------------|
| No Room | Session | 14:00 - 17:30 |
|---------|---------|---------------|

Postgraduate course: PG4 Back to Clinical Physiology  
From Respiratory Mechanics and Gas Exchange to Clinical Physiologic Interventions

**Aims :** To understand the basic principles of respiratory physiology and how they apply to clinical practice.

**Disease(s) :** Pulmonary vascular diseases Respiratory critical care

**Method(s) :** General respiratory patient care Physiology Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs :** William Stringer (Long Beach, United States), Camille Rolland-Debord (Paris, France)

|       |   |
|-------|---|
| 14:00 | <b>From pulmonary gas exchange to the interpretation of arterial blood gases</b><br>Paolo Palange (Rome, Italy)   |
| 14:20 | <b>Discussion and Q&amp;A</b><br>Paolo Palange (Rome, Italy)  |
| 14:30 | <b>Pulmonary circulation: from physiology to clinical applications</b><br>Silvia Ulrich (Zurich, Switzerland)   |
| 14:50 | <b>Discussion and Q&amp;A</b><br>Silvia Ulrich (Zurich, Switzerland)  |
| 15:00 | <b>Break</b>  |
| 15:15 | <b>Respiratory Mechanics and Respiratory Muscle Function</b><br>Caroline Jolley (London, United Kingdom)  |
| 15:35 | <b>Discussion and Q&amp;A</b><br>Caroline Jolley (London, United Kingdom)   |
| 15:45 | <b>The mechanics of breathing in ICU patients, particularly in the era of COVID -19</b><br>Speaker to be confirmed  |
| 16:05 | <b>Discussion and Q&amp;A</b><br>Speaker to be confirmed  |
| 16:15 | <b>Break</b>  |
| 16:30 | <b>Group assignment</b><br>Paolo Palange (Rome, Italy), Silvia Ulrich (Zurich, Switzerland), Caroline Jolley (London, United Kingdom),<br>Speaker to be confirmed |

**No Room** **Session** **08:30 - 12:00****Postgraduate course: PG5 Masterclass in asthma**

**Aims :** To describe methods of diagnosing and managing patients with asthma; to present methods of assessing and treating patients with different asthma phenotypes and monitoring the effects of treatment of asthma based on recent updates.

**Disease(s) :** Airway diseases

**Method(s) :** General respiratory patient care Physiology Public health

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational)

**Chairs :** Omar S. Usmani (London, United Kingdom), Apostolos Bossios (Stockholm, Sweden), Mona Al-Ahmad (Kuwait, Kuwait)

**08:30 Latest updates in the guidelines of Asthma - Diagnosis and Management**  
Ayşe Arzu Yorgancıoğlu (Konak, Turkey)

**08:50 Discussion and Q&A**  
Ayşe Arzu Yorgancıoğlu (Konak, Turkey)

**09:00 Assessing and monitoring Asthma**  
Florence Schleich (Liège, Belgium)

**09:20 Discussion and Q&A**  
Florence Schleich (Liège, Belgium)

**09:30 Break**

**09:45 Making sense of phenotypes and endotypes in Asthma**  
Renaud Louis (Liège, Belgium)

**10:05 Discussion and Q&A**  
Renaud Louis (Liège, Belgium)

**10:15 Pharmacological treatment and current controversies**  
Guy Brusselle (Ghent, Belgium)

**10:35 Discussion and Q&A**  
Guy Brusselle (Ghent, Belgium)

**10:45 Break**

**11:00 Interactive cases by participants**  
Stylianios Loukides (Athens, Greece), Manali Mukherjee (Hamilton (ON), Canada), Ayşe Arzu Yorgancıoğlu (Konak, Turkey)

**No Room** **Session** **14:00 - 17:30****Postgraduate course: PG6 Masterclass in COPD**

**Aims :** To describe methods of diagnosing, assessing and managing patients with COPD, to present methods of assessing and treating patients with different COPD phenotypes and monitoring the effects of treatment of COPD based on recent updates.

**Disease(s) :** Airway diseases

**Method(s) :** Cell and molecular biology General respiratory patient care Physiology

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist

**Chairs :** Omar S. Usmani (London, United Kingdom), Apostolos Bossios (Stockholm, Sweden), Ayşe Arzu Yorgancıoğlu (Konak, Turkey)

**14:00 Latest updates in the guidelines of COPD - Diagnosis and Management**

**14:20 Discussion and Q&A**

**14:30 Assessing and monitoring COPD**  
MeiLan K. Han (Ann Arbor, United States)



**14:50 Discussion and Q&A**  
MeiLan K. Han (Ann Arbor, United States)

---

**15:00 Break**

---

**15:15 Making sense of phenotypes and endotypes in COPD**  
Daiana Stolz (Basel, Switzerland)

---

**15:35 Discussion and Q&A**  
Daiana Stolz (Basel, Switzerland)

---

**15:45 Pharmacological treatment and current controversies**  
Alberto Papi (Ferrara, Italy)

---

**16:05 Discussion and Q&A**  
Alberto Papi (Ferrara, Italy)

---

**16:15 Break**

---

**16:30 Interactive cases by participants**  
Stylios Loukides (Athens, Greece), Miriam Barrecheguren Fernandez (Barcelona, Spain), Daiana Stolz (Basel, Switzerland)

---

**No Room** **Session** **08:30 - 12:00****Postgraduate course: PG7 How to improve research strategies in pneumonia**

**Aims :** The research in pneumonia is usually limited by a number of practical difficulties. We will review limitations and potential advances in this field in order to improve research and the development of future trials in pneumonia from both community and hospital settings

**Disease(s) :** Respiratory infections

**Method(s) :** General respiratory patient care Public health Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

**Chairs :** Eva Polverino (Barcelona, Spain), Chair to be confirmed

**08:30** **Strengths and limitations of clinical trials in pneumonia**  
Tobias Welte (Hannover, Germany)

**08:50** **Discussion and Q&A**  
Tobias Welte (Hannover, Germany)

**09:00** **Advances in microbiological diagnosis for respiratory tract infections**  
Speaker to be confirmed

**09:20** **Discussion and Q&A**  
Speaker to be confirmed

**09:30** **Break**

**09:45** **Definition criteria of pneumonia from the perspective of regulatory agencies**

**10:15** **Adaptative trials in respiratory tract infections**

**10:05** **Discussion and Q&A**

**10:35** **Discussion and Q&A**

**10:45** **Break**

**11:00** **Group assignment**  
Tobias Welte (Hannover, Germany), Speaker to be confirmed

**No Room** **Session** **14:00 - 17:30****Postgraduate course: PG8 The challenges of chronic noninvasive ventilation****A case-based discussion**

**Aims :** The following learning outcomes can be defined:

- to learn about titration of chronic NIV in patients with bulbair complaints; how do we get patients adjusted, what about additional therapies and techniques, when do you decide that with NIV goals are not achieved, when to switch to invasive MV, when decide to stop?
- to learn about titration of chronic NIV in patients with COPD: should we aim for high-intensity NIV, how do we get patients adjusted to high-intensity NIV, what about BURR and in- and expiration times, what about new modes?
- to learn about the detection and clinical consequences of patient-ventilator asynchrony: should we take care for this in chronic care; how can we detect this reliably, what are the clinical consequences?
- to learn about the value of alternative (auto-titrating) modes: should we use AVAPS, EFL titration modes or other alternatives?

**Disease(s) :** Paediatric respiratory diseases Respiratory critical care Sleep and breathing disorders

**Method(s) :** General respiratory patient care Physiology Respiratory intensive care

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Respiratory physiotherapist, Respiratory therapist

**Chairs :** Marieke L. Duiverman (Groningen, Netherlands), Chair to be confirmed

**14:00** **Chronic NIV in patients with bulbair disease: challenges and goals**  
Peter J. Wijkstra (Groningen, Netherlands)

---

|              |  |
|--------------|--|
| <b>14:20</b> | <b>Discussion and Q&amp;A</b><br>Peter J. Wijkstra (Groningen, Netherlands)  |
| <b>14:30</b> | <b>Chronic NIV in patients with COPD: what is the best way to go.</b><br>Sarah Bettina Schwarz (Köln, Germany)   |
| <b>14:50</b> | <b>Discussion and Q&amp;A</b><br>Sarah Bettina Schwarz (Köln, Germany)   |
| <b>15:00</b> | <b>Break</b>   |
| <b>15:15</b> | <b>Patient-ventilator asynchrony: also important in chronic care?</b><br>Michelle Ramsay (Esher, United Kingdom)   |
| <b>15:35</b> | <b>Discussion and Q&amp;A</b><br>Michelle Ramsay (Esher, United Kingdom)   |
| <b>15:45</b> | <b>New NIV modes: what is available and when should it be used?</b><br>Maxime Patout (Mont-Saint Aignan, France)   |
| <b>16:05</b> | <b>Discussion and Q&amp;A</b><br>Maxime Patout (Mont-Saint Aignan, France)   |
| <b>16:15</b> | <b>Break</b>   |
| <b>16:30</b> | <b>Group assignment</b><br>Peter J. Wijkstra (Groningen, Netherlands), Michelle Ramsay (Esher, United Kingdom), Maxime Patout (Mont-Saint Aignan, France), Sarah Bettina Schwarz (Köln, Germany) |

---

| No Room | Session | 08:30 - 12:00 |
|---------|---------|---------------|
|---------|---------|---------------|

**Postgraduate course: PG9 Diagnosing pulmonary hypertension: What a pneumologist should know**

**Aims :** Participants will learn to make the correct diagnosis in pulmonary hypertension in a step wise approach; learn the diagnostic tests in a correct order; interpret the radiology correctly; perform and interpret the right heart catheterisation data correctly; understand right heart physiology and interpret right heart parameters correctly; learn to apply this knowledge in interactive cases

**Disease(s) :** Pulmonary vascular diseases

**Method(s) :** Imaging Physiology Pulmonary function testing

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Radiologist

**Chairs :** Mona Lichtblau (Zürich, Switzerland), Marion Delcroix (Leuven, Belgium), Louise Bouman-van der Waal (Piershil, Netherlands)

|              |   |
|--------------|---|
| <b>08:30</b> | <b>The diagnostic algorithm in pulmonary hypertension</b><br>David Kiely (Sheffield (South Yorkshire), United Kingdom)  |
| <b>08:50</b> | <b>Discussion and Q&amp;A</b><br>David Kiely (Sheffield (South Yorkshire), United Kingdom)  |
| <b>09:00</b> | <b>The radiology of pulmonary hypertension</b><br>Deepa Gopalan (LONDON, United Kingdom)  |
| <b>09:20</b> | <b>Discussion and Q&amp;A</b><br>Deepa Gopalan (LONDON, United Kingdom)   |
| <b>09:30</b> | <b>Break</b>  |
| <b>09:45</b> | <b>Performing and interpreting the right heart catheterisation correctly</b><br>Gabor Kovacs (Graz, Austria)  |
| <b>10:05</b> | <b>Discussion and Q&amp;A</b><br>Gabor Kovacs (Graz, Austria)   |
| <b>10:15</b> | <b>Evaluation of right ventricular function</b><br>Anton Vonk Noordegraaf (Amsterdam, Netherlands)  |
| <b>10:35</b> | <b>Discussion and Q&amp;A</b><br>Anton Vonk Noordegraaf (Amsterdam, Netherlands)  |
| <b>10:45</b> | <b>Break</b>  |
| <b>11:00</b> | <b>Interactive cases</b><br>Athénaïs Boucly (Le Kremlin Bicêtre, France), Mitja Jevnikar (Paris, France), Rui Miguel Costa Adão (Oliveira de Azeméis, Portugal) |

| No Room | Session | 14:00 - 17:30 |
|---------|---------|---------------|
|---------|---------|---------------|

**Postgraduate course: PG10 Spirometry today: From theory to practice**

**Aims :** To understand the basic principles of spirometry and how and to perform it standardized and safe in practice following the new standardization of Spirometry (ATS-ERS) 2019 Update and in/after COVID-19 time.

**Method(s) :** Physiology Pulmonary function testing

**Tag(s) :** Clinical

**Target audience :** Adult pulmonologist/Clinician, General practitioner, Medical Technical Assistant, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

**Chairs :** Pierantonio Laveneziana (Paris, France), Monika Franczuk (Warszawa, Poland)

|              |  |
|--------------|--|
| <b>14:00</b> | <b>The physiological basis of the flow volume curve</b><br>Frans H.C. De Jongh (Enschede, Netherlands) |
| <b>14:20</b> | <b>Discussion and Q&amp;A</b><br>Frans H.C. De Jongh (Enschede, Netherlands)                           |
| <b>14:30</b> | <b>Assuring quality and safety in your spirometry service</b><br>Aisling McGowan (Dublin 15, Ireland)  |

---

|              |   |
|--------------|---|
| <b>14:50</b> | <b>Discussion and Q&amp;A</b><br>Aisling McGowan (Dublin 15, Ireland)   |
| <b>15:00</b> | <b>Break</b>  |
| <b>15:15</b> | <b>Spirometry the practice: Effective performance</b><br>Rachel Ong-Salvador (Amsterdam, Netherlands)   |
| <b>15:35</b> | <b>Discussion and Q&amp;A</b><br>Rachel Ong-Salvador (Amsterdam, Netherlands)   |
| <b>15:45</b> | <b>Spirometry the practice: what can go wrong and how to rectify</b><br>Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)   |
| <b>16:05</b> | <b>Discussion and Q&amp;A</b><br>Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)  |
| <b>16:15</b> | <b>Break</b>  |
| <b>16:30</b> | <b>Group assignment</b><br>Frans H.C. De Jongh (Enschede, Netherlands), Aisling McGowan (Dublin 15, Ireland), Rachel Ong-Salvador (Amsterdam, Netherlands), Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom) |

---

# INDUSTRY SPONSORED SESSIONS



# CHAIR AND COORDINATOR INDEX

Name, Session number

|                                    |                        |
|------------------------------------|------------------------|
| <b>A</b>                           | O'CONNOR G.            |
| ADIR Y.                            | <b>P</b>               |
| AL-AHMAD M.                        | PATOUT M.              |
| ANTONIOU K.                        | PIJNENBURG M.          |
| ARDURA-GARCIA C.                   | PINNOCK H.             |
| <b>B</b>                           | POLVERINO E.           |
| BARRECHEGUREN<br>FERNANDEZ M.      | PROESMANS M.           |
| BLUM T.                            | <b>R</b>               |
| BLYTH K.                           | RAHMAN N.              |
| BONSIGNORE M.                      | RANDERATH W.           |
| BONTEN M.                          | ROBALO CORDEIRO<br>C.  |
| BOSSIOS A.                         | ROLLAND-DEBORD C.      |
| BOUMAN-VAN DER<br>WAAL L.          | <b>S</b>               |
| BRADICICH M.                       | SCHIZA S.              |
| <b>C</b>                           | SIMONDS A.             |
| CHOROSTOWSKA-<br>WYNIMKO J.        | SITBON O.              |
| CRAVEN R.                          | SOTGIU G.              |
| <b>D</b>                           | STOLZ D.               |
| DE WEVER W.                        | STRINGER W.            |
| DELCROIX M.                        | SUPPLI ULRİK C.        |
| DEMEYER H.                         | <b>T</b>               |
| DINH-XUAN A.                       | TESTELMANS D.          |
| DUIVERMAN M.                       | TROOSTERS T.           |
| <b>F</b>                           | <b>U</b>               |
| FRANCZUK M.                        | ULRICH S.              |
| FRANSSEN F.                        | UNGER S.               |
| <b>G</b>                           | USMANI O.              |
| GAPPA M.                           | <b>V</b>               |
| GARCIA AYMERICH J.                 | VERGES S.              |
| GOMPELMANN D.                      | VONK<br>NOORDEGRAAF A. |
| GONZALEZ BERMEJO<br>J.             | <b>W</b>               |
| GOSENS R.                          | WELTE T.               |
| GRABCZAK E.                        | WINCK J.               |
| GREENE C.                          | <b>Y</b>               |
| <b>H</b>                           | YORGANCIO LU A.        |
| HARARI S.                          |                        |
| HARDAVELLA G.                      |                        |
| HEUNKS L.                          |                        |
| HUMBERT M.                         |                        |
| <b>K</b>                           |                        |
| KEIR H.                            |                        |
| KELLY E.                           |                        |
| KOCKS J.                           |                        |
| KONTOGIANNI K.                     |                        |
| KREUTER M.                         |                        |
| <b>L</b>                           |                        |
| LAURSEN C.                         |                        |
| LAVENEZIANA P.                     |                        |
| LICHTBLAU M.                       |                        |
| <b>M</b>                           |                        |
| MASKELL N.                         |                        |
| MEINERS S.                         |                        |
| MELONI F.                          |                        |
| MÖLLER A.                          |                        |
| MONTEIRO<br>DRUMMOND FREITAS<br>M. |                        |
| MOOR K.                            |                        |
| <b>O</b>                           |                        |

# DISCUSSANT INDEX

Name, Session number

## B

BUSH A.

## C

CHALMERS J.

CHARPIDOU A.

## D

DUIVERMAN M.

## G

GAGA M.

GAPPA M.

## H

HEUNKS L.

## J

JANES S.

JIMÉNEZ CASTRO D.

## M

MIRAVITLLES M.

MOLINA MOLINA M.

## S

SPAGNOLO P.

STOLZ D.

## U

ULRICH S.

# SPEAKER INDEX

Name, Presentation number

|                               |                           |                       |                           |                 |
|-------------------------------|---------------------------|-----------------------|---------------------------|-----------------|
| <b>A</b>                      | EVERAERTS S.              | LEE G.                | RAUCH A.                  | <b>Y</b>        |
| AGUSTI GARCIA-<br>NAVARRO A.  | <b>F</b>                  | LEVETT D.             | REDOLFI S.                | YORGANCIO LU A. |
| AKDIS C.                      | FAHY J.                   | LICHTBLAU M.          | RENZONI E.                | <b>Z</b>        |
| ALMENDROS LOPEZ I.            | FARVER-<br>VESTERGAARD I. | LIPMAN M.             | RICE M.                   | ZAR H.          |
| ANNESI MAESANO I.             | FAUROUX B.                | LOMBARDI C.           | RIHA R.                   | ZUILY S.        |
| ANTONIOU K.                   | FERINI S.                 | LOMBARDI E.           | ROBINSON P.               |                 |
| ASCIAK R.                     | FITZGERALD D.             | LOUIS R.              | RØMHILD DAVIDSEN<br>J.    |                 |
| <b>B</b>                      | FOWLER S.                 | LOUKIDES S.           | ROSENFELD M.              |                 |
| BACKER V.                     | FROIDURE A.               | LOWE D.               | RYAN S.                   |                 |
| BAFADHEL M.                   | <b>G</b>                  | LUNDBERG I.           | <b>S</b>                  |                 |
| BANKA R.                      | GAGA M.                   | <b>M</b>              | SANCHEZ O.                |                 |
| BARBERÀ MIR J.                | GAINÉ S.                  | MAGLIONE P.           | SANCHEZ DE LA<br>TORRE M. |                 |
| BARRECHEGUREN<br>FERNANDEZ M. | GAPPA M.                  | MALPASS A.            | SCHAEFFER M.              |                 |
| BA O LU Ò.                    | GIBELLINI L.              | MANGIAPAN G.          | SCHIZA S.                 |                 |
| BENDIXEN M.                   | GOPALAN D.                | MARTÍNEZ GARCÍA<br>M. | SCHLEICH F.               |                 |
| BENDSTRUP E.                  | <b>H</b>                  | MASKELL N.            | SCHRAMM D.                |                 |
| BENZO R.                      | HABIB M.                  | MAZZOLAI L.           | SCHWARZ S.                |                 |
| BERASTEGUI GARCIA<br>C.       | HAIJZADEH N.              | MCAULEY D.            | SEDDON J.                 |                 |
| BEYDON N.                     | HALLIFAX R.               | MCCARTHY C.           | SHAKESPEARE J.            |                 |
| BIBBY A.                      | HAN M.                    | MCGOWAN A.            | SIDDIQUI S.               |                 |
| BOGAERT D.                    | HARRISON S.               | MCNAMARA P.           | SILLEN M.                 |                 |
| BOKAN A.                      | HART N.                   | MELGERT B.            | SIMONDS A.                |                 |
| BONELLA F.                    | HEINZER R.                | MERCER R.             | SINGH D.                  |                 |
| BOUCLY A.                     | HERNÁNDEZ R.              | MEYTS I.              | SINGH S.                  |                 |
| BRACKE K.                     | HEUNKS L.                 | MIRAVITLLES M.        | SKEVAKI C.                |                 |
| BROCHARD L.                   | HIGGINS I.                | MOLINA MOLINA M.      | SMITH J.                  |                 |
| BRUSSELLE G.                  | HOEPER M.                 | MOOKHERJEE N.         | SPAGNOLO P.               |                 |
| BURTIN C.                     | HOFFMANN-VOLD A.          | MUKHERJEE M.          | STOLZ D.                  |                 |
| BUSH A.                       | HOLLAND A.                | MÜLLER V.             | SYK J.                    |                 |
| <b>C</b>                      | HOLMES E.                 | MURPHY P.             | SYLVESTER K.              |                 |
| CALFEE C.                     | HUMBERT M.                | <b>N</b>              | <b>T</b>                  |                 |
| CAMUS P.                      | <b>J</b>                  | NAVA S.               | TACCONELLI E.             |                 |
| CARRIER M.                    | JANES S.                  | NAVALESÍ P.           | TAZI MEZALEK R.           |                 |
| CAVALERI M.                   | JANSSSEN J.               | NELSON-PIERCY C.      | THOMEER M.                |                 |
| CHALMERS J.                   | JAVAHERI S.               | NOSENT E.             | TINGAY D.                 |                 |
| CHARPIDOU A.                  | JENY F.                   | NUNES H.              | TSILIGIANNI I.            |                 |
| CHAVANNES N.                  | JEVNIKAR M.               | <b>O</b>              | TSIM S.                   |                 |
| CHOI A.                       | JIMÉNEZ CASTRO D.         | O'DONNELL D.          | <b>U</b>                  |                 |
| CHOROSTOWSKA-<br>WYNIMKO J.   | JOHNSON M.                | ONG-SALVADOR R.       | UBAGS N.                  |                 |
| COSTA ADÃO R.                 | JOLLEY C.                 | <b>P</b>              | ULRICH S.                 |                 |
| COUTURAUD F.                  | JONES S.                  | PALANGE P.            | USMANI O.                 |                 |
| CRESTANI B.                   | <b>K</b>                  | PANERONI M.           | <b>V</b>                  |                 |
| CUNNINGHAM-<br>RUNDLES C.     | KAHLMANN V.               | PANOU V.              | VAN MEERBEECK J.          |                 |
| <b>D</b>                      | KANTAR A.                 | PAPI A.               | VELTKAMP M.               |                 |
| D'CRUZ R.                     | KARAGIANNIDIS C.          | PATAKA A.             | VERGES S.                 |                 |
| DE JONGH F.                   | KIELY D.                  | PATOUT M.             | VERHAMME K.               |                 |
| DE WEVER W.                   | KLION A.                  | PÉPIN J.              | VICENTE C.                |                 |
| DELCROIX M.                   | KNEYBER M.                | PERCH M.              | VOLPICELLI G.             |                 |
| DEMEYER H.                    | KOCKS J.                  | PETTIGREW M.          | VONK<br>NOORDEGRAAF A.    |                 |
| DERDE L.                      | KOLB M.                   | PIETERSEN P.          | VOS R.                    |                 |
| DINH-XUAN A.                  | KONTOGIANNI K.            | PINELLI V.            | <b>W</b>                  |                 |
| DOLEZAL B.                    | KOVACS G.                 | PIQUILLOUD L.         | WAINWRIGHT C.             |                 |
| DUIVERMAN M.                  | KRAFT M.                  | POUWELS S.            | WARE L.                   |                 |
| <b>E</b>                      | KREUTER M.                | PRICE L.              | WAXMAN A.                 |                 |
| EKELUND U.                    | <b>L</b>                  | PROESMANS M.          | WELTE T.                  |                 |
| EKSTRÖM M.                    | LANGE C.                  | PROSCH H.             | WIJKSTRA P.               |                 |
| ELBORN S.                     | LANGER D.                 | PSALLIDAS I.          | WIJSENBECK M.             |                 |
| ELIA S.                       | LANKEIT M.                | <b>R</b>              | WINDISCH W.               |                 |
|                               | LAROU MAGNE               | RAHMAN N.             | WRIGHTSON J.              |                 |
|                               | DUMETRE S.                | RAMSAY M.             |                           |                 |
|                               | LAVENEZIANA P.            | RANDERATH W.          |                           |                 |

# AUTHOR INDEX

Name, Abstract number